Share on StockTwits

ResMed (NYSE:RMD) Insider David Pendarvis unloaded 5,000 shares of the company’s stock in a transaction that occurred on Thursday, July 3rd. The stock was sold at an average price of $50.04, for a total transaction of $250,200.00. Following the completion of the sale, the insider now directly owns 69,207 shares of the company’s stock, valued at approximately $3,463,118. The sale was disclosed in a legal filing with the SEC, which is available at this link.

A number of research firms have recently commented on RMD. Analysts at Deutsche Bank downgraded shares of ResMed from a “buy” rating to a “hold” rating in a research note on Thursday. They now have a $52.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of ResMed in a research note on Wednesday, June 11th. They now have a $55.00 price target on the stock. Finally, analysts at JPMorgan Chase & Co. upgraded shares of ResMed from a “neutral” rating to an “overweight” rating in a research note on Tuesday, June 10th. One analyst has rated the stock with a sell rating, eight have given a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $46.90.

ResMed (NYSE:RMD) traded down 0.94% on Monday, hitting $49.61. 693,291 shares of the company’s stock traded hands. ResMed has a 1-year low of $41.52 and a 1-year high of $57.34. The stock’s 50-day moving average is $51.20 and its 200-day moving average is $47.27. The company has a market cap of $6.962 billion and a P/E ratio of 21.97.

ResMed (NYSE:RMD) last announced its earnings results on Wednesday, April 23rd. The company reported $0.63 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.64 by $0.01. The company had revenue of $397.80 million for the quarter, compared to the consensus estimate of $401.00 million. During the same quarter last year, the company posted $0.58 earnings per share. ResMed’s revenue was up 3.7% compared to the same quarter last year. On average, analysts predict that ResMed will post $2.49 earnings per share for the current fiscal year.

ResMed Inc, (NYSE:RMD) is a holding company for the ResMed Group.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.